Supplements

Insight: Signalling in cancer

Vol. 441, No. 7092 pp423-457

Thirty years of oncogene research have provided fascinating insights into the molecular basis of cancer. Many hurdles remain in the race to beat cancer, but as the articles in this Insight show, a growing understanding of the complex signalling pathways that underlie tumour formation and progression is driving the development of a new generation of anticancer drugs targeted at specific molecular events. All content is FREE ACCESS for 6 months.

In this supplement

• Editorial
• Reviews

Editorial

Signalling in cancer

Alex Eccleston and Ritu Dhand

doi:10.1038/441423a

Full Text | PDF (147KB)

Reviews

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Reuben J. Shaw and Lewis C. Cantley

doi:10.1038/nature04869

Abstract | Full Text | PDF (512KB)

Nuclear factor-κB in cancer development and progression

Michael Karin

doi:10.1038/nature04870

Abstract | Full Text | PDF (1546KB)

Hypoxia signalling in cancer and approaches to enforce tumour regression

Jacques Pouysségur, Frédéric Dayan and Nathalie M. Mazure

doi:10.1038/nature04871

Abstract | Full Text | PDF (748 KB)

New signals from the invasive front

Gerhard Christofori

doi:10.1038/nature04872

Abstract | Full Text | PDF (752 KB)

Validating cancer drug targets

John D. Benson, Ying-Nan P. Chen, Susan A. Cornell-Kennon, Marion Dorsch, Sunkyu Kim, Magdalena Leszczyniecka, William R. Sellers and Christoph Lengauer

doi:10.1038/nature04873

Abstract | Full Text | PDF (255 KB)

Mechanisms of drug inhibition of signalling molecules

Judith S. Sebolt-Leopold and Jessie M. English

doi:10.1038/nature04874

Abstract | Full Text | PDF (427 KB)